Guichuang Medical's ZYLOX Octoplus™ venous filter was approved by NMPA for marketing

December 14,$ZYLOXTB (02190.HK)$Its peripheral intervention division Guichuang Medical announced that its self-developed ZYLOX Octoplus™ venous venous filter has been approved for marketing by the National Drug Administration (NMPA), which is expected to provide more comprehensive safety guarantees for high-risk deep venous thrombosis patients.

The ZYLOX Octoplus™ venous filter is a new generation of medical devices innovatively developed by Guichuang Medical for the prevention and treatment of deep vein thrombosis and pulmonary embolism diseases. The innovative structural design of the ZYLOX Octoplus™ venous filter has excellent instantaneous vena vena wall adhesion performance and excellent autonomous balance. The filter has accurate release and is effective in blocking blood clots over a long period of time. The ZYLOX Octoplus™ venous filter can reduce the risk of pulmonary embolism, give patients a longer window of thrombolysis treatment, increase the cure rate of deep vein thrombosis, reduce the medical burden on patients, and improve patients' quality of life. The name of the ZYLOX Octoplus™ venous venous filter comes from the words “Octopus (octopus)” and “Plus (excellent)”, reflecting the characteristics of this product's “A New Chapter in Enyuesheng Huiyou Spectrum”.

Deep vein thrombosis is a common vascular disease. Thrombosis can cause fatal pulmonary artery embolism, seriously threatening the lives and safety of patients. According to the company's prospectus, the number of cases of deep vein thrombosis in China is expected to increase from 1.5 million cases in 2019 to 3.3 million in 2030, with a compound annual growth rate of 7.3%. Due to its advantages, interventional surgery has become the preferred treatment for deep vein thrombosis. Among them, the number of inferior venous filter implants is expected to increase from 85,700 in 2019 to 673,700 in 2030, with a compound annual growth rate of 20.6%.

The pre-marketing clinical trial of the ZYLOX Octoplus™ venous filter independently developed by Guichuang Medical was led by Professor Liu Jianlong of Beijing Jishuitan Hospital. Nine well-known domestic peripheral vascular intervention centers, including Nanjing First Hospital, Beijing Friendship Hospital Affiliated to Capital Medical University, First Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Qingdao University Affiliated Hospital, Second Affiliated Hospital of Soochow University, Wenzhou People's Hospital, and Xi'an Honghui Hospital, participated in the pre-marketing clinical trial. The test results fully demonstrated the clinical safety and efficacy of the ZYLOX Octoplus™ venous filter.

At present, the company has 19 products approved for sale by NMPA, and 8 products have obtained EU CE certification. In the future, Guichuang Tongqiao will continue to uphold the original intention of “constant innovation for patients” to provide patients and doctors with more comprehensive and efficient products and solutions, so that more patients can enjoy the high quality of life brought by advanced medical technology.

27K Views